Dr. Andrea Vanzulli: New Response Criteria for Solid Tumors | ASCO 2024

In this OncoDaily episode, Dr. Andrea Vanzulli, a third-year radiology resident at the National Cancer Institute in Milan, presents his ASCO 2024 study on developing new response criteria for solid tumors, with a focus on soft tissue sarcomas. His research highlights the limitations of traditional RECIST criteria and demonstrates a strong inverse correlation between radiologic objective responses and clinical outcomes. Dr. Vanzulli's findings emphasize the need for more tailored and granular assessment criteria to better predict patient outcomes. Abstract:- https://doi.org/10.1200/JCO.2024.42.16_suppl.11553 #SoftTissueSarcoma #TumorResponse #RadiologicResponse #OncologyResearch #ASCO2024 #RECISTLimitations #ClinicalOutcomes #CancerDiagnosis #InterventionalRadiology #OncoDaily #Oncology #Cancer #CancerTreatment #MedicalInnovation #SarcomaCare #CancerResearch #Radiology #DiagnosticRadiology #TumorAssessment #MedicalAdvancements #RadiologyUpdates #AndreaVanzulli SUBSCRIBE to get the latest #oncodaily https://www.youtube.com/@OncoDailyTV Visit the OncoDaily Website : https://oncodaily.com Like OncoDaily on LinkedIn: https://linkedin.com/company/oncodaily Like OncoDaily on X (Twitter): https://x.com/oncodaily Follow OncoDaily on Instagram: https://www.instagram.com/oncodailynews/ Follow OncoDaily on TikTok: https://www.tiktok.com/@oncodaily Like OncoDaily on Facebook: https://www.facebook.com/oncodaily/ SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter About OncoDaily OncoDaily is a world-leading oncology media platform, which is based in the United States and features the cancer related latest news, insights, and patient stories from around the globe. The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”